CaaMTech is a startup pharmaceutical company specializing in psychedelic drug research, development, and intellectual property. The founder and CEO of CaaMTech is Dr. Andrew Chadeayne.
CaaMTech’s work focuses on the fundamentals of psychedelic science. The foundation rests on the concept that understanding compounds from a chemical and pharmacological standpoint is the essential first step in drug discovery. They point out that psilocybin is only one compound in the cocktail that is present in magic mushrooms, for example. Instead of therapies based on a single compound, CaaMTech encourages researchers and clinicians to consider the entourage effect in magic mushrooms, ayahuasca, and DMT, among many others. This opens the door to realizing the full array of capabilities and benefits of these natural compounds. Applying these foundational scientific concepts, CaaMTech plans to deliver technological innovation and intellectual property in the psychedelic space.
CaaMTech summarizes its drug research and development strategy on their website. “Most conventional pharmaceutical products offer just one active ingredient in a precise dose. Natural organisms contain multiple active molecules in varying concentrations and ratios, working in harmony to produce a multitude of pharmacological effects. Between lies the vast and understudied territory of psychedelic formulations. By providing precise amounts of multiple active ingredients, psychedelic formulations allow consumers to access the superior properties of the natural organisms along with the safety, consistency, and reliability of pharmaceutical products.”
Recently, CaaMTech announced they have formed a partnership with the Designer Drug Research Unit of the National Institutes of Health (NIH). The collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
Dr. Chadeayne and his research teams a CaaMTech have authored several papers on the crystal structure of tryptamine compounds including 4-AcO-DMT (psilacetin), MPT, norpsilocin, and 5-MeO-DALT.1–8 The characterization of these compounds in conjunction with the NIH is critical for developing safe and effective psychedelic drugs.